Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
Status:
Recruiting
Trial end date:
2024-12-11
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, non-randomized, multicenter phase II study to evaluate the
efficacy of spartalizumab in monotherapy in metastatic patients with Programmed Death-1
(PD1)-high-expressing tumors.